Cargando…

Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)

Efflux transporters, namely ATP-binding cassette (ABC), are one of the primary reasons for cancer chemoresistance and the clinical failure of chemotherapy. Ganciclovir (GCV) is an antiviral agent used in herpes simplex virus thymidine kinase (HSV-TK) gene therapy. In this therapy, HSV-TK gene is del...

Descripción completa

Detalles Bibliográficos
Autores principales: Markowicz-Piasecka, Magdalena, Huttunen, Johanna, Montaser, Ahmed, Adla, Santosh Kumar, Auriola, Seppo, Lehtonen, Marko, Huttunen, Kristiina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303380/
https://www.ncbi.nlm.nih.gov/pubmed/34299347
http://dx.doi.org/10.3390/ijms22147727
_version_ 1783727072981549056
author Markowicz-Piasecka, Magdalena
Huttunen, Johanna
Montaser, Ahmed
Adla, Santosh Kumar
Auriola, Seppo
Lehtonen, Marko
Huttunen, Kristiina M.
author_facet Markowicz-Piasecka, Magdalena
Huttunen, Johanna
Montaser, Ahmed
Adla, Santosh Kumar
Auriola, Seppo
Lehtonen, Marko
Huttunen, Kristiina M.
author_sort Markowicz-Piasecka, Magdalena
collection PubMed
description Efflux transporters, namely ATP-binding cassette (ABC), are one of the primary reasons for cancer chemoresistance and the clinical failure of chemotherapy. Ganciclovir (GCV) is an antiviral agent used in herpes simplex virus thymidine kinase (HSV-TK) gene therapy. In this therapy, HSV-TK gene is delivered together with GCV into cancer cells to activate the phosphorylation process of GCV to active GCV-triphosphate, a DNA polymerase inhibitor. However, GCV interacts with efflux transporters that are responsible for the resistance of HSV-TK/GCV therapy. In the present study, it was explored whether GCV and its more lipophilic derivative (1) could inhibit effluxing of another chemotherapeutic, methotrexate (MTX), out of the human breast cancer cells. Firstly, it was found that the combination of GCV and MTX was more hemocompatible than the corresponding combination with compound 1. Secondly, both GCV and compound 1 enhanced the cellular accumulation of MTX in MCF-7 cells, the MTX exposure being 13–21 times greater compared to the MTX uptake alone. Subsequently, this also reduced the number of viable cells (41–56%) and increased the number of late apoptotic cells (46–55%). Moreover, both GCV and compound 1 were found to interact with breast cancer resistant protein (BCRP) more effectively than multidrug-resistant proteins (MRPs) in these cells. Since the expression of BCRP was higher in MCF-7 cells than in MDA-MB-231 cells, and the cellular uptake of GCV and compound 1 was smaller but increased in the presence of BCRP-selective inhibitor (Fumitremorgin C) in MCF-7 cells, we concluded that the improved apoptotic effects of higher MTX exposure were raised mainly from the inhibition of BCRP-mediated efflux of MTX. However, the effects of GCV and its derivatives on MTX metabolism and the quantitative expression of MTX metabolizing enzymes in various cancer cells need to be studied more thoroughly in the future.
format Online
Article
Text
id pubmed-8303380
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83033802021-07-25 Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP) Markowicz-Piasecka, Magdalena Huttunen, Johanna Montaser, Ahmed Adla, Santosh Kumar Auriola, Seppo Lehtonen, Marko Huttunen, Kristiina M. Int J Mol Sci Article Efflux transporters, namely ATP-binding cassette (ABC), are one of the primary reasons for cancer chemoresistance and the clinical failure of chemotherapy. Ganciclovir (GCV) is an antiviral agent used in herpes simplex virus thymidine kinase (HSV-TK) gene therapy. In this therapy, HSV-TK gene is delivered together with GCV into cancer cells to activate the phosphorylation process of GCV to active GCV-triphosphate, a DNA polymerase inhibitor. However, GCV interacts with efflux transporters that are responsible for the resistance of HSV-TK/GCV therapy. In the present study, it was explored whether GCV and its more lipophilic derivative (1) could inhibit effluxing of another chemotherapeutic, methotrexate (MTX), out of the human breast cancer cells. Firstly, it was found that the combination of GCV and MTX was more hemocompatible than the corresponding combination with compound 1. Secondly, both GCV and compound 1 enhanced the cellular accumulation of MTX in MCF-7 cells, the MTX exposure being 13–21 times greater compared to the MTX uptake alone. Subsequently, this also reduced the number of viable cells (41–56%) and increased the number of late apoptotic cells (46–55%). Moreover, both GCV and compound 1 were found to interact with breast cancer resistant protein (BCRP) more effectively than multidrug-resistant proteins (MRPs) in these cells. Since the expression of BCRP was higher in MCF-7 cells than in MDA-MB-231 cells, and the cellular uptake of GCV and compound 1 was smaller but increased in the presence of BCRP-selective inhibitor (Fumitremorgin C) in MCF-7 cells, we concluded that the improved apoptotic effects of higher MTX exposure were raised mainly from the inhibition of BCRP-mediated efflux of MTX. However, the effects of GCV and its derivatives on MTX metabolism and the quantitative expression of MTX metabolizing enzymes in various cancer cells need to be studied more thoroughly in the future. MDPI 2021-07-20 /pmc/articles/PMC8303380/ /pubmed/34299347 http://dx.doi.org/10.3390/ijms22147727 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Markowicz-Piasecka, Magdalena
Huttunen, Johanna
Montaser, Ahmed
Adla, Santosh Kumar
Auriola, Seppo
Lehtonen, Marko
Huttunen, Kristiina M.
Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
title Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
title_full Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
title_fullStr Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
title_full_unstemmed Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
title_short Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
title_sort ganciclovir and its hemocompatible more lipophilic derivative can enhance the apoptotic effects of methotrexate by inhibiting breast cancer resistance protein (bcrp)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303380/
https://www.ncbi.nlm.nih.gov/pubmed/34299347
http://dx.doi.org/10.3390/ijms22147727
work_keys_str_mv AT markowiczpiaseckamagdalena gancicloviranditshemocompatiblemorelipophilicderivativecanenhancetheapoptoticeffectsofmethotrexatebyinhibitingbreastcancerresistanceproteinbcrp
AT huttunenjohanna gancicloviranditshemocompatiblemorelipophilicderivativecanenhancetheapoptoticeffectsofmethotrexatebyinhibitingbreastcancerresistanceproteinbcrp
AT montaserahmed gancicloviranditshemocompatiblemorelipophilicderivativecanenhancetheapoptoticeffectsofmethotrexatebyinhibitingbreastcancerresistanceproteinbcrp
AT adlasantoshkumar gancicloviranditshemocompatiblemorelipophilicderivativecanenhancetheapoptoticeffectsofmethotrexatebyinhibitingbreastcancerresistanceproteinbcrp
AT auriolaseppo gancicloviranditshemocompatiblemorelipophilicderivativecanenhancetheapoptoticeffectsofmethotrexatebyinhibitingbreastcancerresistanceproteinbcrp
AT lehtonenmarko gancicloviranditshemocompatiblemorelipophilicderivativecanenhancetheapoptoticeffectsofmethotrexatebyinhibitingbreastcancerresistanceproteinbcrp
AT huttunenkristiinam gancicloviranditshemocompatiblemorelipophilicderivativecanenhancetheapoptoticeffectsofmethotrexatebyinhibitingbreastcancerresistanceproteinbcrp